Association of Cerebral Microbleeds With Cognitive Decline and Dementia

Saloua Akoudad1, Frank J Wolters2, Anand Viswanathan3

  • 1Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands2Department of Radiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands3Department of Neurology, Erasmus MC, University Me.

JAMA Neurology
|June 9, 2016
PubMed
Abstract

Insights

High counts of cerebral microbleeds are linked to cognitive decline and dementia in the general population. These microbleeds indicate widespread brain damage from vascular and neurodegenerative causes.

Area of Science:

  • Neurology
  • Neuroimaging
  • Epidemiology

Background:

  • Cerebral microbleeds (CMBs) are potential indicators of brain damage from vascular and amyloid pathologies.
  • Their association with cognitive decline in the general population remains uncertain.

Purpose of the Study:

  • To investigate if CMB presence, count, and location correlate with an increased risk of cognitive impairment and dementia.
  • To explore the relationship between CMBs and cognitive deterioration in a general population cohort.

Main Methods:

  • The Rotterdam Study, a prospective population-based cohort, analyzed 4841 participants aged 45+.
  • Brain MRI was used to detect CMBs; participants underwent repeated neuropsychological testing and dementia follow-up.
  • Statistical analyses included multiple linear regression, mixed-effects modeling, and Cox proportional hazards models.

Main Results:

  • 15.3% of participants had CMBs. More than 4 CMBs were associated with cognitive decline.
  • Lobar CMBs correlated with declines in executive function, information processing, and memory.
  • CMBs increased the risk for dementia (HR, 2.02) and Alzheimer's dementia (HR, 2.10) after adjusting for covariates.

Conclusions:

  • A higher number of cerebral microbleeds is associated with increased risk of cognitive decline and dementia in the general population.
  • CMBs serve as markers for diffuse vascular and neurodegenerative brain damage.
  • These findings highlight the clinical relevance of CMBs in predicting cognitive outcomes.

Related Concept Videos

Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
663
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
1.1K